A Phase I Study of BLU-285 in Patients with Inoperable Gastrointestinal Stromal Tumors

Full Title

BLU-285-1101: A Phase 1 Study of BLU-285 in Patients with Gastrointestinal Stromal Tumors (GIST) and other Relapsed and Refractory Solid Tumors


The purpose of this study is to assess the safety and preliminary effectiveness of the investigational drug BLU-285 in patients with inoperable gastrointestinal stromal tumors (GIST) that have come back or continued to grow despite prior treatment or which have a particular genetic mutation. BLU-285 works by inhibiting the actions of certain enzymes that GIST needs to grow. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable GIST that has either come back after treatment with imatinib and another kinase inhibitor OR a genetic mutation in the tumor called PDGFR-alpha D842V.
  • At least 2 weeks must pass since the completion of any prior anticancer treatment and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. William Tap at 636-888-4163.